0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Doxorubicin"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
Gynecological Cancer Drugs Market Report 2025 - Product Thumbnail Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Soft Tissue Sarcoma Market Report 2025 - Product Thumbnail Image

Soft Tissue Sarcoma Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Sarcoma Drugs Market Report 2025 - Product Thumbnail Image

Sarcoma Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
Osteosarcoma Global Market Report 2025 - Product Thumbnail Image

Osteosarcoma Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
EUR$4,490USDGBP
From
EUR$4,490USDGBP
Sarcoma Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Sarcoma Therapeutics - Global Strategic Business Report

  • Report
  • July 2025
  • 180 Pages
  • Global
From
EUR$5,850USDGBP
Soft Tissue Sarcoma - Global Strategic Business Report - Product Thumbnail Image

Soft Tissue Sarcoma - Global Strategic Business Report

  • Report
  • July 2025
  • 282 Pages
  • Global
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
From
EUR$5,850USDGBP
From
EUR$2,999USDGBP
From
EUR$2,999USDGBP
From
EUR$7,950USDGBP
Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
EUR$3,000USDGBP
Metastatic Urothelial Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Urothelial Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
EUR$2,000USDGBP
Soft Tissue Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Soft Tissue Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
EUR$3,000USDGBP
Follicular Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

Follicular Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
EUR$2,500USDGBP
B-cell Lymphoma- Pipeline Insight, 2025 - Product Thumbnail Image

B-cell Lymphoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
EUR$5,000USDGBP
Clear Cell Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Clear Cell Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
EUR$1,250USDGBP
Anaplastic Large Cell Lymphoma - Pipeline Insight, 2025 - Product Thumbnail Image

Anaplastic Large Cell Lymphoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
EUR$1,250USDGBP
Loading Indicator

Doxorubicin is an oncology drug used to treat a variety of cancers, including leukemia, lymphoma, and breast, ovarian, and bladder cancer. It is a type of anthracycline antibiotic, derived from Streptomyces peucetius, and works by interfering with the growth of cancer cells. It is administered intravenously, and is often used in combination with other drugs. Doxorubicin is one of the most widely used chemotherapy drugs, and is often used in combination with other drugs to treat a variety of cancers. It is also used to treat Kaposi's sarcoma, a type of skin cancer. Side effects of doxorubicin include nausea, vomiting, hair loss, and an increased risk of infection. The doxorubicin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more